Video Library

F. Stephen Hodi, MD, Director of the Center for Immuno-Oncology spoke at our Joint Visiting Committee Symposium and discussed how researchers are engaging a patient’s own immune system to fight their cancer. This less toxic treatment has shown great promise in melanoma and other cancers.

DF/BWCC now creates a precise "tumor profile" of genomic changes that helps physicians more accurately diagnose the subtype of a patient's cancer, predict its behavior and help select precisely targeted therapy

In this video Dana-Farber's George Demetri, MD, explains how a blood test can provide fuller picture of cancer mutations in gastrointestinal stromal tumors (GIST) than biopsy.

James Bradner, MD, Medical Oncologist, describes what it takes to assemble the building blocks in research that lead to cures for cancer. This brief talk to donors at Dana-Farber's Joint Visiting Committee Symposium gives a glimpse into his research in cancer chemical biology, which is helping Dana-Farber pave the way to a world without cancer.

Kai W. Wucherpfennig, MD, PhD, Co-chair of the Department of Immunology and AIDS at Dana-Farber, describes how immunology research contributes to the fight against cancer and the development of new and promising cancer treatments for patients.

Jeff was diagnosed with advanced lung cancer that had spread to his brain. His tumor tested positive for the ALK gene translocation so his treatment changed from chemotherapy to a targeted therapy that was more effective and had fewer side effects. Four years later, Jeff is still doing well.

Edward Benz, President and Chief Executive at Dana-Farber Cancer Institute, speaks about precision cancer medicine at the TEDx UMass Boston "Lighting the Way for the Future"

Levi Garraway, MD, PhD, Director, Center for Cancer Precision Medicine at Dana-Farber Cancer Institute spoke about Dana-Farber’s groundbreaking work in precision medicine in this brief talk at the November 2014 SIDTALKS - Science, Innovation, and Discovey at Dana-Farber.

Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene (ALK) are likely to fare better if treated with the targeted therapy (crizotinib) than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.